SCIENTIFIC PROGRAMME OVERVIEW

Friday 20 June 2008

Session 6: Aetiology of sarcoidosis
Chair: L.Newman, J.Domagala-Kulawik

• 09:00 OP3: Mycobacterial heat shock proteins in the etiopathogenesis of sarcoidosis
  Anna Dubaniewicz
  Department of Pathophysiology, Medical University of Gdansk, Poland
• 09:10 W.P Drake: Why we think sarcoidosis is due to mycobacterial infection?
• 09:30 L.Newman: Why we look for causes of sarcoidosis other than mycobacteria ?
• 09:50 Q+A

Session 7: Pathogenesis of sarcoidosis and IPF
Chair: J.Grunewald, A.Wells
Speakers:

• 10:00 T.Handa: Potential role for co-stimulatory molecules and CD-8 positive lymphocytes in sarcoidosis.
• 10:20 J.Grunewald: Pathogenesis of sarcoidosis
• 10:40 N.Poulakis: Decreased expression of heme oxygenase-1 by alveolar macrophages in IPF
• 11:00 A.Wells: Pathogenesis of IPF
• 11:20 Q+A

Session 8. Genetics of sarcoidosis and IPF
Chair: R.DuBois, D.Papakosta
Speakers:

• 12:00 R.DuBois: Genetics of IPF
• 12:20 OP4 : Prognostical value of clinical and genetic factors on radiological outcome in sarcoidosis
  Wijnen P.1,2, Nelemans P.3, Bekers O.1, Drent M.2,4
  1 Dept. of Clinical Chemistry, Maastricht University Medical Center (MUMC), 2 ild care center, MUMC, 3 Dept. of Epidemiology, University Maastricht, 4 Dept. of Respiratory Medicine, MUMC, Maastricht, the Netherlands
• 12:30 C.Saltini: Genetics of sarcoidosis
• 12:50 Q + A

Session 9: Session 9. Extrathoracic sarcoidosis
Chair: M.Judson, V.Michailovic-Vucinic
Speakers:

• 13:00 OP5 : Clinical Study on Hepatic Involvement of Sarcoidosis Teruo Tachibana1,Arata Azuma2,Shinobu Takenaka3,Mikio Kataoka4,Takeshi Ishizaki5,Masahiro Nishikawa6, Mitunori Sakatan7
  1Aizenbashi Hospital,0saka, 2Nippon Medical School, Pulmonary Medicine,Tokyo, 3Kumamoto City Hospital, 4Okayama University, 5Fukui University, 6Nishinomiya Hsospital, 7National Kinki- Chuuou Chest Disease Hospital,Osaka, Japan
• 13:10 OP6 : Clinical manifestations, radiographic findings, treatment options and outcome in sarcoidosis patients with upper respiratory tract involvement
  Panselinas E1, Halstead L2, Schlosser RJ2, Judson MA2
  1. Sismanoglion Hospital, Athens, Greece 2. Medical University of South Carolina, Charleston, South Carolina USA
• 13:20 OP7: Specific cutaneous lesions of sarcoidosis. Relationship to systemic disease
  Mana J.1. Rubio M.1, Marcoval J.2
  1. Department of Internal Medicine, 2. Department of Dermatology Bellvitge University Hospital, Barcelona, Spain
• 13:30 M.Judson: The three Clinical Aspects of Extrapulmonary Sarcoidosis
• 14:00 Q + A

NOON BREAK
Poster Sessions (6,7,8,9) in Room B. Details: see poster session pages

Session 10: Management of sarcoidosis
Chair: M.Drent, O.Sharma
Speakers:

• 18:00 OP8: Treatment of lupus pernio
  Stagaki E.1, Mountford W.2, Lackland D.2, Judson M.2
  1. Sismanoglio General Hospital of Attica, Athens, Greece
  2. Medical University of South Carolina, Charleston, South Carolina, USA
• 18:10 OP9: Inhaled corticosteroides in treatment of pulmonary sarcoidosis
  J.Videnovic-Ivanov, V.Vucinic, S.Filipovic, J.Stojsic, N.Vasic:
  Institute for lung diseases and tuberculosis, Clinical Centre of Serbia, Belgrade
• 18:20 D.Moeller: Approach to sarcoidosis therapy based on cytokine manipulations
• 18:40 R.P.Baughman: Fatigue for sarcoidosis: treat the symptom
• 19:00 M.Drent: Fatigue from sarcoidosis: treat the cause
• 19:20 Q+A

Satellite Symposium: Idiopathic pulmonary hypertention and pulmonary fibrosis associated pulmonary hypertention, recognition and management. (Sponsored by VIPharma International S.A.) s

Chair:D.Israel-Biet, R.P.Baughman

Speakers:

• 19:30 J.Carlsen: PAH aetiology and management/guidelines
• 19:55 R.P.Baughman: PAH and CTD
• 20:20 L.Howard: Thelin: The selective ETRA, from Pharmacology to Clinical trials
• 20:45 Q+A